Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03623945 · ClinicalTrials.gov registry record
Autoantibodies in Breast Cancer Detection
A clinical trial, sponsored by Sanford Health.
- Terminated
- Registry status
- 1,279
- Enrollment target
NCT03623945: Clinical Trial study, sponsored by Sanford Health.
NCT03623945 is a clinical trial that was terminated before completion, run by Sanford Health. The registered enrollment target is 1,279 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03623945 was terminated before completion, sponsored by Sanford Health.
- TERMINATED
- Registry status
- 1,279 participants
- Enrollment target
Study Summary
Prospective, single-center study in women who have recently had an abnormal mammogram followed by a breast biopsy or women who have recently had a normal screening mammogram. We are no longer enrolling women who had normal Screening mammograms.
Primary Outcome
The data from Phase I will be tested and validated with newly diagnosed BCa patient samples from Cohort A, and age-matched healthy controls taken from Cohort D, and a risk score will be developed based on a composite of autoantibodies for breast cancer diagnosis. A Cox Proportional Hazards (PH) Regression will be used to analyze a case-cohort study design to validate the risk score by identifying breast cancer cases from those cases in Cohorts B, C and D.
Interventions
- OTHER Collection of blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,279 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2024-03-11 |
Why NCT03623945 stopped before completion
NCT03623945 is an observational study that tracks outcomes without assigning an intervention. Its 1,279 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Collection of blood is the first listed.
NCT03623945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03623945 about?
NCT03623945 is a clinical study titled "Autoantibodies in Breast Cancer Detection". Prospective, single-center study in women who have recently had an abnormal mammogram followed by a breast biopsy or women who have recently had a normal screening mammogram. We are no longer enrolling women who had normal Screening mammograms.
What is the current status of trial NCT03623945?
This trial is currently terminated. The enrollment target is 1,279 participants. The study started on 2018-07-24. Estimated completion is 2024-03-11.
What interventions are being tested in trial NCT03623945?
The interventions under investigation include: Collection of blood (OTHER).
Who is sponsoring clinical trial NCT03623945?
This trial is sponsored by Sanford Health, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI